Medical Oncologist
Endocrine (hormone) therapy is one of the most effective treatments for hormone-receptor-positive breast cancer, but it is taken for years, so its side effects matter to daily life. Tamoxifen and aromatase inhibitors cause different problems — hot flashes and a small clot risk with one, joint pain and bone loss with the other. Almost all of these can be eased, and at CION a woman-led team helps you stay on treatment comfortably, because hormone-positive breast cancer responds best when the full course is finished.
Hormone therapy — also called endocrine therapy — is given when a breast cancer is hormone-receptor-positive, meaning its cells are fuelled by the body's own estrogen. The treatment works by lowering estrogen or blocking it from reaching the cancer cells. That is exactly why it causes side effects: estrogen also supports many other tissues — the brain's temperature control, the bones, the joints and the vagina — so reducing it produces symptoms that feel like an intense, drug-induced menopause.
There are two main groups. Tamoxifen blocks the estrogen receptor in breast tissue and can be used at any age. Aromatase inhibitors stop the body making estrogen and are used mainly after menopause (or alongside ovarian suppression in younger women). Because these tablets are usually taken for five to ten years, knowing what to expect — and that almost every side effect can be managed — helps you complete the course that protects you from recurrence.
Endocrine therapy is a long course, not a short one. That is why side effects matter day-to-day — and why managing them well is part of the treatment, not an afterthought.
Tamoxifen and aromatase inhibitors lower or block estrogen in different ways, so their side-effect profiles are quite distinct. Your symptoms depend partly on which one you take.
Hot flashes, joint pain, bone loss and vaginal symptoms can almost all be eased with simple measures — so quietly stopping the tablet is rarely the right answer.
Studies show that up to 1 in 2 women stop their hormone tablets early or take them irregularly, most often because of side effects they never reported. Yet completing the full course substantially lowers the risk of breast cancer returning. The lesson is simple: side effects should be treated, not silently endured — tell your oncologist before you stop. Source: NCCN Breast Cancer guidance; published endocrine-therapy adherence studies.
Tamoxifen works by sitting on the estrogen receptor so estrogen cannot switch on the cancer. In breast tissue it acts as a blocker, but in a few other tissues it acts a little like estrogen — which explains its particular pattern of side effects. Most women tolerate it well; the common effects are bothersome rather than dangerous, while two uncommon risks need awareness. You can read more on our dedicated tamoxifen page.
The most common complaint — sudden waves of heat, flushing and sweating, often worse at night. They tend to settle over the first few months and can be eased with non-hormonal options, covered on our menopause symptoms page.
Vaginal dryness or discharge, reduced libido, mood swings and tiredness can occur. These are usually manageable, and intimacy concerns can be addressed openly — see intimacy after treatment.
Tamoxifen slightly raises the risk of clots in the legs (DVT) or lungs. The absolute risk is low, but tell your doctor of any leg swelling, pain or breathlessness, and mention it before long flights or surgery.
In postmenopausal women, tamoxifen can slightly increase the risk of changes in the womb lining, including a small rise in endometrial cancer risk. Report any unusual vaginal bleeding promptly — it is usually benign but always worth checking.
Aromatase inhibitors are a group of tablets used mainly after menopause. Instead of blocking the receptor, they stop the body converting other hormones into estrogen, driving estrogen levels very low. They do not carry tamoxifen's clot or womb risks, but the deep drop in estrogen produces a different set of effects — most notably in the joints and the bones. Knowing these helps you and your team act early.
Aching, stiffness or pain in the hands, knees, hips and back — often worst in the morning — is the signature side effect. It is real, not imagined, and frequently improves with gentle movement, weight management and dose adjustments.
Because estrogen protects bone, aromatase inhibitors can accelerate bone loss and raise fracture risk. A bone-density scan at the start and during treatment lets your team protect your bones before a problem develops.
Menopausal-type symptoms also occur, sometimes more intensely than with tamoxifen because estrogen is suppressed so strongly. Non-hormonal management works well for most women.
Fatigue, low mood and sleep disturbance can appear, partly from poor sleep due to night sweats and joint pain. Addressing the underlying symptom often lifts the energy and mood too.
Neither group is "better" — the right choice depends on whether you are pre- or postmenopausal, your bone and clot risk, and how you tolerate each drug. Sometimes the team switches between them during the years of treatment to find the one you tolerate best. The goal is always the same: keep you on effective hormone therapy with the fewest possible symptoms.
Tamoxifen can be used before or after menopause. Aromatase inhibitors are for postmenopausal women, or for younger women combined with ovarian suppression to switch off the ovaries.
Tamoxifen leans toward hot flashes, with small clot and womb-lining risks. Aromatase inhibitors lean toward joint pain and bone loss. Both can cause menopausal symptoms.
If side effects on one drug are hard to live with, the team can switch you to the other group, or change to a different aromatase inhibitor — many women tolerate one far better than another.
On aromatase inhibitors, the focus is bone-density monitoring and protection. On tamoxifen, the focus is clot awareness and reporting unusual bleeding. Your team tailors monitoring to your drug.
Side effects spread over years are exactly where good supportive care makes the difference between finishing treatment and quietly giving up. CION is a woman-headed, tumour-board-led organisation that treats your symptoms as seriously as your cancer — so you stay protected and stay comfortable.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Woman-led, tumour-board-reviewed care that treats side effects as seriously as the cancer — across 35+ centres in Telangana & AP. Call 1800-202-8726.
Almost every side effect of endocrine therapy has a practical answer. The key is to report symptoms early rather than soldier on, because there is usually a simple step that helps. Crucially, standard hormone replacement therapy (HRT) is generally avoided in breast cancer survivors, so the focus is on non-hormonal measures — these are covered in detail on our menopause and hot flashes page.
Your CION team works through these with you visit by visit, adjusting as your symptoms change over the years of treatment.
Most hormone-therapy side effects are uncomfortable but not dangerous. A few, however, deserve a prompt call to your oncology team rather than waiting for the next appointment. Knowing which is which puts you in control without making you anxious.
It is tempting to stop a tablet that causes daily discomfort, especially once you feel well. But endocrine therapy is one of the most powerful tools we have to stop hormone-positive breast cancer from coming back. Completing the full five to ten years substantially lowers the risk of recurrence compared with stopping early — and stopping quietly, without telling your team, removes that protection while better options for the side effects go untried.
The honest message we give patients: side effects are real and deserve treatment, but they are almost never a reason to abandon a course that is protecting your future. Tell us, and we will help you finish it.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
You do not have to choose between protection and quality of life. CION offers a clear, woman-led pathway to manage side effects across the whole course of endocrine therapy — with your first consultation free.
A specialist reviews your diagnosis, the tablet you are on, and the side effects you are having — and explains the options, with no rushed decisions and no unnecessary tests.
We tailor management to your drug — clot and bleeding awareness on tamoxifen, joint and bone protection on aromatase inhibitors — with up to 50% discounts on diagnostics like bone-density scans.
If a drug is hard to tolerate, the tumour board reviews whether a switch or dose change keeps you protected with fewer symptoms — rather than stopping altogether.
Nutrition, psycho-oncology, bone health and intimacy support continue through the years of treatment, so you finish the course that protects you.
Hear from patients treated at CION — diagnosis, treatment path, and where they are today.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
It depends on which tablet you take. Tamoxifen most often causes hot flashes and night sweats, sometimes with vaginal dryness, mood changes and tiredness; it also carries a small risk of blood clots and, in postmenopausal women, womb-lining changes. Aromatase inhibitors most often cause joint and muscle pain, bone thinning, and menopausal symptoms such as hot flashes. Both groups can affect mood, sleep and intimacy. The good news is that nearly all of these can be eased with simple measures, non-hormonal medicines or, where needed, a switch of drug — so you can usually stay on the treatment that protects you.
Tamoxifen blocks the estrogen receptor and can be used at any age; its typical issues are hot flashes, a small clot risk, and a slight increase in womb-lining changes in postmenopausal women. Aromatase inhibitors stop the body making estrogen and are used mainly after menopause; they do not carry tamoxifen's clot or womb risks, but they cause more joint pain and bone loss because they drive estrogen very low. Many women tolerate one far better than the other, so if side effects are hard to live with, your oncologist can often switch you between the two groups while keeping you protected.
Standard hormone replacement therapy (HRT) is generally avoided in breast cancer survivors, so management is non-hormonal. Practical steps help: light, layered clothing, a cool bedroom, a handheld fan, and cutting back on caffeine, alcohol and spicy food, which can trigger flashes. Regular exercise, weight management and good sleep habits make a real difference. When flashes are severe, several non-hormonal prescription medicines genuinely reduce their frequency and intensity, and your oncologist can recommend one. Our menopause and hot flashes page covers these options in more detail. Report severe flashes rather than enduring them — there is almost always something that helps.
They can. Because estrogen protects bone, aromatase inhibitors lower estrogen so much that they can accelerate bone loss and raise the risk of fracture over the years of treatment. This is a known, manageable effect — not a reason to avoid the drug. Your team should arrange a baseline bone-density (DEXA) scan and repeat it during treatment, and recommend calcium, vitamin D and weight-bearing exercise. If your bone density is low, a bone-strengthening medication can protect you while you stay on treatment. At CION, bone health is built into follow-up for women on aromatase inhibitors, with up to 50% discounts on diagnostics like DEXA scans.
Hormone therapy can cause a sudden, steep drop in estrogen — much faster than the gradual decline of natural menopause — which is why hot flashes and night sweats can feel more intense. Aromatase inhibitors in particular suppress estrogen very strongly. For younger women, treatment-induced menopause from chemotherapy or ovarian suppression can be especially abrupt. The symptoms are real and deserve treatment, but because HRT is usually avoided after breast cancer, the focus is on non-hormonal management. Our menopause symptoms page explains why HRT is avoided and what works instead, including lifestyle steps and non-hormonal medicines.
Please talk to your oncologist before stopping — do not stop quietly on your own. Endocrine therapy substantially lowers the risk of hormone-positive breast cancer returning, and that protection is lost if you stop early. The reassuring part is that there is almost always a Plan B: easing the side effect with non-hormonal measures or medicines, lowering the dose, taking a short break, or switching to a different drug that you may tolerate much better. Stopping treatment should be a shared, informed decision made with your team as a last resort, not a private decision driven by side effects that could have been managed.
Many side effects, especially hot flashes, are worst in the first few months and then settle as your body adjusts, though some persist through treatment. Joint pain from aromatase inhibitors can develop over the first months and often improves with movement and management. Most side effects ease within weeks to a few months of finishing the course, although menopausal symptoms may linger for a while if the treatment brought on menopause. Bone loss is cumulative and is why monitoring continues during treatment. The key point is that side effects lasting through the course can almost always be managed so they do not stop you completing it.
Yes. CION offers a free first consultation for all cancer patients, including women already on hormone therapy who are struggling with side effects or considering stopping. It is a full 45-minute consultation — a specialist reviews your diagnosis and the tablet you are on, builds a symptom-management plan tailored to your drug, arranges bone-density monitoring where needed, and considers whether a switch or dose change would help. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.